Get started
IVN on the move againAs you can see from my markups on the Daily chart, Ivanhoe Mines (#IVN) is on the on the move again however has a couple of major milestones to break through... As you can see we have two trend-lines we are approaching, one being a shorter term ascending trend-line, the other being a longer term descending trend-line. Historically, IVN trades well when working with trend-lines so I am anxious to see this round how we respond to the upcoming/approaching trend-lines. Overall I am bullish on IVN. I am looking to make a higher-high to the ascending trend line. Lets wait to see how this pans out. Cheers everyone and remember, trade safe!
TSX:IVNLong
by SpoTT77
First Majestic: Refinishing…Like an artist with their painting, a craftsperson with their handiwork or a cook with their most exquisite dish, First Majestic seems not yet ready to let go of its work in the turquoise zone between $12.36 and $6.89 and apparently wants to add a finishing touch. Thus, it has arched back downwards and could aim for completing wave 2 in turquoise a bit deeper still in the turquoise zone. As soon as the current downwards movement is concluded, though, First Majestic should turn upwards and head for the resistance at $19.41. However, there is a remarkable 45% chance that First Majestic could break through the bottom of the turquoise zone and drop below the support at $5.30, which would then trigger further downwards movement.
TSX:AG
by MarketIntel
$NRX.V Outpaces Biotech Peers Following TSX.V Listing The biotech sector is presenting exciting opportunities for investors despite the broader downturn in global equity markets. Many of the best biotech companies and ETFs have both strong drug candidate pipelines in the works as well as winning drugs and therapeutic products already on the market. The COVID-19 pandemic has proven and created massive opportunities for the biotechnology sector as a whole, particularly so around innovative players that are developing therapeutic solutions with disruptive potential. One new player to the field is Nurexone Biologic (NRX.V), a new listee on the TSXV exchange that is redefining exosome therapeutics for application to traumatic brain and spinal cord injuries. It is creating a platform for biologically-guided ExoTherapy that will be administered minimally invasively to patients who have had catastrophic spinal cord injuries. Since July 15th, NRX +26% as it attracts new investors and institutional players begin to trade the equity. In comparison, the TSX/SPX composite index charted 6% gains, indicating that NRX far outperformed the market baseline over the course of the summer rally. Relative to sectoral ETFs, Nurexone is also trading strong. IBBQ is +6.9% and XBI +6% over the same timeframe NRX is +26%; it is important to note that over this period, the company did not release any price sensitive announcements that would otherwise account for its significant bullish price movement. Further, exosome-based equities are one area of the wider biotech industry that has continuously traded robustly despite subpar performance for equity markets this year. Sectoral competitors are mixed bag, with KMPH +4.8% while APTO is down 4.4%. Kodiak Biosciences (KOD) jumped 20%, though it still lags behind NRX's 26% increase. This indicates that as exosome therapeutic developers struggle to maintain forward momentum amidst the backdrop of a challenging macroeconomic landscape, NRX is outperforming both sectoral ETFs and direct competitors. Though its a newby to capital markets, so far Nurexone is standing out as the bullish outlier with LT potential.
TSXV:NRX
by BiotechBrandon